Health Insurance Innovations, Inc. (NASDAQ:HIIQ)‘s stock had its “buy” rating reiterated by analysts at Canaccord Genuity in a report issued on Friday. They presently have a $39.00 price objective on the financial services provider’s stock, up from their prior price objective of $30.00. Canaccord Genuity’s price target points to a potential upside of 23.03% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on the company. Craig Hallum restated a “buy” rating and set a $38.00 price objective (up from $28.00) on shares of Health Insurance Innovations in a research report on Thursday. Cantor Fitzgerald restated an “overweight” rating and set a $35.00 price objective (up from $30.00) on shares of Health Insurance Innovations in a research report on Monday, July 17th. Zacks Investment Research downgraded Health Insurance Innovations from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Raymond James Financial, Inc. restated a “market perform” rating on shares of Health Insurance Innovations in a research report on Monday, June 26th. Finally, TheStreet upgraded Health Insurance Innovations from a “c” rating to a “b-” rating in a research report on Monday, May 22nd. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Health Insurance Innovations currently has a consensus rating of “Buy” and an average price target of $30.83.

Shares of Health Insurance Innovations (HIIQ) traded up 7.09% during midday trading on Friday, hitting $31.70. The stock had a trading volume of 911,774 shares. The company’s 50 day moving average is $25.25 and its 200 day moving average is $20.08. The company has a market cap of $366.14 million, a PE ratio of 25.65 and a beta of 0.68. Health Insurance Innovations has a 52-week low of $3.90 and a 52-week high of $32.95.

Health Insurance Innovations (NASDAQ:HIIQ) last issued its quarterly earnings data on Wednesday, August 2nd. The financial services provider reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.13. Health Insurance Innovations had a return on equity of 23.92% and a net margin of 5.56%. The business had revenue of $61.80 million for the quarter, compared to the consensus estimate of $53.69 million. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. On average, analysts anticipate that Health Insurance Innovations will post $1.48 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/06/health-insurance-innovations-inc-nasdaqhiiq-given-buy-rating-at-canaccord-genuity.html.

In other news, insider Sheldon Wang sold 4,750 shares of the stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $25.80, for a total value of $122,550.00. Following the sale, the insider now directly owns 224,001 shares in the company, valued at $5,779,225.80. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Bruce Telkamp sold 24,179 shares of the stock in a transaction that occurred on Wednesday, May 10th. The stock was sold at an average price of $20.25, for a total value of $489,624.75. Following the completion of the sale, the chief executive officer now owns 116,501 shares in the company, valued at $2,359,145.25. The disclosure for this sale can be found here. Over the last quarter, insiders sold 256,983 shares of company stock worth $6,283,895. Company insiders own 30.00% of the company’s stock.

Several large investors have recently modified their holdings of the company. Bank of Montreal Can acquired a new stake in shares of Health Insurance Innovations during the first quarter valued at $118,000. Acrospire Investment Management LLC increased its stake in shares of Health Insurance Innovations by 36.8% in the first quarter. Acrospire Investment Management LLC now owns 11,505 shares of the financial services provider’s stock valued at $184,000 after buying an additional 3,094 shares during the last quarter. Rhumbline Advisers acquired a new stake in shares of Health Insurance Innovations during the second quarter valued at $277,000. Sheets Smith Wealth Management acquired a new stake in shares of Health Insurance Innovations during the second quarter valued at $280,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Health Insurance Innovations by 11.5% in the first quarter. Bank of New York Mellon Corp now owns 12,270 shares of the financial services provider’s stock valued at $197,000 after buying an additional 1,266 shares during the last quarter. Hedge funds and other institutional investors own 71.94% of the company’s stock.

Health Insurance Innovations Company Profile

Health Insurance Innovations, Inc is a developer, distributor and cloud-based administrator of individual and family health insurance plans (IFPs) and supplemental products, which include short-term medical (STM) insurance plans, and guaranteed-issue and underwritten hospital indemnity plans. The Company also develops, distributes and administers supplemental products, which include a range of additional insurance and non-insurance products, such as pharmacy benefit cards, dental plans, vision plans, cancer/critical illness plans, deductible and gap protection plans, and life insurance policies that are purchased as supplements to IFP.

Analyst Recommendations for Health Insurance Innovations (NASDAQ:HIIQ)

Receive News & Ratings for Health Insurance Innovations Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Insurance Innovations Inc. and related companies with MarketBeat.com's FREE daily email newsletter.